PRM.L Stock - Proteome Sciences plc
Unlock GoAI Insights for PRM.L
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $4.89M | $5.03M | $23.74B | $22.59B | $16.95B |
| Gross Profit | $670,000 | $1.65M | $4.77M | $2.96M | $2.58M |
| Gross Margin | 13.7% | 32.8% | 0.0% | 0.0% | 0.0% |
| Operating Income | $-2,353,000 | $-1,621,000 | $1.73M | $412,000 | $549,000 |
| Net Income | $-3,406,000 | $-2,443,000 | $1.32M | $72,000 | $295,000 |
| Net Margin | -69.7% | -48.6% | 0.0% | 0.0% | 0.0% |
| EPS | $-0.01 | $-0.01 | $0.00 | $0.00 | $0.00 |
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, and European Union. The company offers SysQuant provides comprehensive analysis of protein activity across regulatory and signaling pathways; TMT MS2 for analyzing cells and tissues when no phosphopeptide enrichment is required; and TMT MS3, a method for biomarker discovery in plasma and other complex samples where quantitative accuracy is the important factor. It also provides TMT Calibrator that analyzes diseased or treated tissue in parallel with peripheral fluids; TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates; and SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers. In addition, the company offers bioinformatics tools, including Proteome Discoverer for peptide sequence and TMT quantitation; SQuaT,CalDIT, and DIANA for normalized quantitative values and functional annotation at peptide and protein level; FeaST for visualization of data quality, class identifier model, and biomarker candidate lists; and FAT for identification of biological processes and cellular components showing variance. It primarily serves pharmaceutical and biotechnology companies, and academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.
Visit WebsiteEarnings History & Surprises
PRM.LEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 8, 2026 | — | — | — | — |
Q3 2025 | Sep 11, 2025 | — | $-0.01 | — | — |
Q2 2025 | Apr 10, 2025 | — | $-0.00 | — | — |
Q3 2024 | Sep 13, 2024 | — | $-0.01 | — | — |
Q2 2024 | Apr 10, 2024 | — | $-0.01 | — | — |
Q3 2023 | Sep 19, 2023 | — | $-0.00 | — | — |
Q2 2023 | Apr 4, 2023 | — | $0.00 | — | — |
Q2 2022 | Jun 30, 2022 | — | $0.00 | — | — |
Q4 2021 | Dec 31, 2021 | — | $0.00 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.00 | — | — |
Q4 2020 | Dec 31, 2020 | — | $0.00 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.00 | — | — |
Q4 2019 | Dec 31, 2019 | — | $0.00 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.00 | — | — |
Q4 2018 | Dec 31, 2018 | — | $0.00 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.00 | — | — |
Q4 2017 | Dec 31, 2017 | — | $-0.00 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-0.00 | — | — |
Q4 2016 | Dec 31, 2016 | — | $-0.00 | — | — |
Q2 2016 | Jun 30, 2016 | — | $-0.01 | — | — |
Latest News
Frequently Asked Questions about PRM.L
What is PRM.L's current stock price?
What is the analyst price target for PRM.L?
What sector is Proteome Sciences plc in?
What is PRM.L's market cap?
Does PRM.L pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to PRM.L for comparison